Cybin is conducting clinical trials with a number of tryptamines to treat a plethora of disorders. Today it was awarded a patent for its proprietary DMT analogue CYB004, which it hopes will treat anxiety disorders.
PSYCH sat down with Cybin’s CEO Doug Drysdale to discuss the organisation’s drug development pipeline and plans for 2022.
READ MORE
Dr Spriggs of Imperial College London spoke with Neo.Life on treating anorexia with psychedelic-assisted therapy.
Read More
The state may only allow the use of Psilocybe cubensis, so small growers can gain a foothold in the emerging market.
Read MoreMydecine to supply Canada’s Special Access Program.
Medigus invests US$1.25m in Clearmind.
Psychedelic ETF launches on NYSE.
Optimi Health granted Dealer’s Licence by Health Canada.
Cybin secures patent for proprietary DMT derivative.
Novamind to host Alto Neuroscience’s Phase II trials.
A beginner’s guide to DMT.
Little Green Pharma and Reset Mind Sciences to demerge.
Psychedelic wellness’ growing presence in North Texas.
The 200+ page Psychedelics as Medicine Report: Third Edition is the most comprehensive analysis of the psychedelic healthcare industry, empowering investors, operators and regulators to make informed decisions.
Key findings:
Ketamine for suicidal ideation.
Psychedelics and the future of psychiatry.
Are psychedelics dangerous? What the research says.
Can MDMA save a marriage?
Can microdosing psychedelics boost mental health?
Microdosing zebrafish with LSD shows its potential benefits for humans.
Are psychedelics the future of pain relief?
Health Canada denies dozens of requests to access psilocybin.
Bill to legalise psilocybin-assisted therapy fails in Maine.
Utah lawmakers vote to study benefits of psychedelic medicines.
Seattle doctor files DEA petition to reschedule psilocybin.
Advocates in Michigan file ballot initiative to decriminalise entheogens.
DEA faces backlash over proposed scheduling of tryptamines.
Experts in Washington say psilocybin can be a pathway to treatment.
